MedTrace Logo

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

NCT06058585 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-04-01

No results posted yet for this study

Summary

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).

CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.

CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

Conditions

  • Chronic Kidney Diseases

Interventions

DRUG

Finerenone

Finerenone 10mg or 20mg tablets, oral, once daily

DRUG

Placebo Finerenone

Finerenone matched placebo tablets, oral, once daily

Sponsors & Collaborators

  • The George Institute

    lead OTHER

Principal Investigators

  • Sradha Kotwal · The George Institute

  • Hiddo Lambers Heerspink · The George Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-04
Primary Completion
2028-08-30
Completion
2029-03-31

Countries

  • Australia
  • India
  • New Zealand
  • Spain
  • Sri Lanka

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06058585 on ClinicalTrials.gov